50 related articles for article (PubMed ID: 21521025)
1. Association of TNFα
Peddireddy V; Badabagni SP; Sulthana S; Kolla VK; Gundimeda SD; Mundluru H
Int J Clin Oncol; 2016 Oct; 21(5):843-852. PubMed ID: 27282611
[TBL] [Abstract][Full Text] [Related]
2. Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1/2.
Chen CM; Hsieh YH; Hwang JM; Jan HJ; Hsieh SC; Lin SH; Lai CY
Tumour Biol; 2015 May; 36(5):3407-15. PubMed ID: 25527158
[TBL] [Abstract][Full Text] [Related]
3. Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression.
Huang HC; Tsai LL; Tsai JP; Hsieh SC; Yang SF; Hsueh JT; Hsieh YH
Tumour Biol; 2014 Dec; 35(12):12139-49. PubMed ID: 25149157
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype.
Li Z; Guo Y; Jiang H; Zhang T; Jin C; Young CY; Yuan H
BMC Cancer; 2014 Apr; 14():276. PubMed ID: 24755270
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-to-mesenchymal transition markers to predict response of Berberine in suppressing lung cancer invasion and metastasis.
Qi HW; Xin LY; Xu X; Ji XX; Fan LH
J Transl Med; 2014 Jan; 12():22. PubMed ID: 24456611
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis.
Wang J; Cai Y
Tumour Biol; 2012 Dec; 33(6):1819-28. PubMed ID: 22718017
[TBL] [Abstract][Full Text] [Related]
7. Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway.
Liang H; Gu M; Yang C; Wang H; Wen X; Zhou Q
J Anesth; 2012 Jun; 26(3):381-92. PubMed ID: 22349744
[TBL] [Abstract][Full Text] [Related]
8. The Amazing Power of Cancer Cells to Recapitulate Extraembryonic Functions: The Cuckoo's Tricks.
Arias JI; Aller MA; Prieto I; Arias A; de Julian Z; Yang H; Arias J
J Oncol; 2012; 2012():521284. PubMed ID: 21969829
[TBL] [Abstract][Full Text] [Related]
9. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma.
Chetty C; Rao JS; Lakka SS
Pharmacogenomics; 2011 Apr; 12(4):535-46. PubMed ID: 21521025
[TBL] [Abstract][Full Text] [Related]
11. No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma.
Wang Y; Fang S; Wei L; Wang R; Jin X; Wen D; Li Y; Guo W; Wang N; Zhang J
Lung Cancer; 2005 Aug; 49(2):155-61. PubMed ID: 15949868
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
[TBL] [Abstract][Full Text] [Related]
13. SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients.
Osawa K
Pharmacogenomics; 2011 Apr; 12(4):445-7. PubMed ID: 21521014
[No Abstract] [Full Text] [Related]
14. Pharmacogenomics in non-small-cell lung cancer chemotherapy.
Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R
Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
